# Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

> **NCT04174170** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 591 (actual)

## Conditions studied

- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** Brexpiprazole
- **DRUG:** Sertraline
- **OTHER:** Placebo
- **DRUG:** Brexpiprazole

## Key facts

- **NCT ID:** NCT04174170
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-30
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-08-15
- **Target enrollment:** 591 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04174170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04174170, "Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04174170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*